Precision medicine (also known as personalized medicine) uses information about a person’s genes, proteins, and environment to prevent, diagnose, and treat cancer. Precision medicine includes the use of biomarkers, molecular testing, and targeted therapies to deliver a personalized approach to cancer therapy through the use of molecular and genomic information about individual cancers. The National Cancer Institute (NCI) defines precision medicine as “discovering unique therapies that treat an individual’s cancer based on the specific abnormalities of their tumor.”
ACCC develops comprehensive Precision Medicine resources that bring clarity to complex patient care decisions. Designed for multidisciplinary cancer teams, the resources enable clinicians to make educated and holistic decisions that can positively influence patient outcomes. No matter your learning style—podcasts, on-demand webinars, videos, or publications—the ACCC Precision Medicine Library has resources that provide essential knowledge you can apply to your patient care.
Join this interactive webinar to hear a review of how the steps in the life cycle of a patient specimen can affect its molecular integrity and molecular analysis results.
Two thought leaders who have deep knowledge of—and experience in—biomarker testing in patients with hematologic malignancies will discuss best practices for biomarker testing in chronic lymphocytic leukemia (CLL) and multiple myeloma based on patient case discussions and the latest guidelines.
Bispecific antibodies are an emerging class of novel immunotherapy agents that have led to major breakthroughs in treating hematologic malignancies—and have promising applications for solid tumors.
Addresses the role of laboratory medicine professionals and pathologists in biomarker testing, incorporating a review of testing techniques and applications, lab-specific regulations, and the impact of those regulations on biomarker testing.
Learn about open opportunities to participate in an ACCC-supported QI project, then see how ACCC's online self-assessment tools can help identify areas of improvement at your program or practice.
Key issues in high integrity tissue acquisition facing community cancer programs. (December 17, 2020)
Gain important and practical information for the assessment of measurable residual disease as part of routine clinical practice for patients with chronic lymphocytic leukemia (CLL).
Genetic Testing and Implementation of Cancer Genomics in Clinical Care was part of the Oncology State Societies at ACCC Virtual Symposium on Friday, November 13, 2020.
Webinar topics include biomarker basics, inherited cancers, laboratory medicine, cost and coverage, and tumor-specific case examples.
Deep dive into the differences between germline and somatic mutations, with case examples, and presentation of findings from the LUNGevity/FORCE patient survey.
We will review current policies and regulations that drive costs related to biomarker testing.
Introduction to cancer biomarkers, relevant terminology, and implications for cancer care.
An insightful and thought-provoking discussion about the expanding role and importance of early engagement of pathologists—the laboratory physicians who guide, develop, and implement biomarker testing.
Stephen Quake, PhD, spoke to CANCER BUZZ about the application of liquid biopsies across multiple cancer stages and their potential to improve patient outcomes, minimize financial toxicity, and create health equity through greater testing access and lower cost.
While not yet mainstream in the community setting, hear how measurable residual disease (MRD) testing has the potential to become more fully integrated into clinical practice as one of the reliable markers of treatment response for patients with multiple myeloma and chronic lymphocytic leukemia.
Simplifying and standardizing pathology reports so patients are better informed, understand their prognosis, and own the progress of their therapies is of critical importance in today's episode.
In this episode, hear from two experts in cancer immunotherapy on the exciting potential of TIL Cell Therapy in melanoma and beyond.
Biomarker testing is crucial to precision medicine, but barriers still exist. Learn from two healthcare advocates about recent policy changes designed to ensure better access to biomarker testing.
Hear from Colleen Campbell, PhD, MS, LGC, as she explains policy changes that can help patients access genetic counseling services, while also benefiting those who provide these services.
Hear from two authors of an ACCC/LUNGevity Foundation study that identified key areas of clinician need related to biomarker testing in NSCLC.
Genetic counselors—as members of the cancer care team—can help patients better understand their cancer diagnosis, make informed treatment decisions, and navigate the financial costs of testing.
Learn about the current clinical applications of liquid biopsies, associated reimbursement issues, and what you can do to implement these tests at your program.
Learn how genetic healthcare services have adapted to virtual care delivery, and what challenges face its widespread use after the COVID-19 pandemic is over.
By evaluating the unique genetic makeup of specific individuals, precision medicine can enable clinicians to select the safest and most effective therapies for their patients. By using the tools of precision medicine—such as biomarker testing—physicians can diagnose cancer types and select treatment regimens with the most potential to successfully target an individual tumor’s specific mutations. While precision medicine in cancer care is becoming more widespread, its rapid evolution in oncology requires ongoing discussion.
ACCC’s podcast, CANCER BUZZ, features lively expert discussions about emergent issues in cancer care. Precision medicine and all of its implications are frequent topics. The following episodes feature new perspectives on precision medicine in cancer care:
Biomarker Testing Advocacy: Biomarker testing is an important part of precision medicine; however, many commercial health plans and state Medicaid programs do not provide adequate coverage for these services. But recent legislative wins may mean things are changing. We speak to two healthcare advocates to discuss recent policy changes as they relate to biomarker testing.
Precision Medicine Disparities: Authors of an ACCC/LUNGevity Foundation study that identifies key areas of clinician need related to biomarker testing in non-small cell lung cancer discuss the need for more knowledge about precision medicine guidelines, the practical applications of guideline-concordant testing, the importance of patient-clinician discussion and education, and access to appropriate clinical trials.
Genetic Testing & Telehealth: Uncover common barriers to genetic counseling and biomarker testing for patients with cancer and learn how providers can help expand the use of testing and counseling delivered via telehealth to educate, inform, and improve patient care.
What You Need to Know about Liquid Biopsy: Learn about the current clinical applications of liquid biopsies, their associated reimbursement issues, and what can be done to implement these tests at cancer programs and practices.
Telehealth & Genetics During COVID-19: Explore how genetic healthcare services have adapted to virtual delivery and what challenges there are to the widespread use of telehealth medicine after the pandemic is over.
The Promise of Bispecific Antibodies: The redirection of T cells against tumors holds significant promise for the treatment of cancer. Learn about promising breakthroughs, the challenges to widespread use, and what cancer teams need to know about the future of cancer treatment.
Immunotherapy (IO) & Dermatology: Immune-related adverse events most often present on the skin for patients undergoing immunotherapy. Learn about dermatology’s role in the cancer care continuum and how cancer teams can better integrate dermatology into the IO care process.
IO Clinical Trials During COVID-19: Learn how immunotherapy clinical trials have been affected by the pandemic and what cancer programs can do to conduct clinical trials safely and effectively during the pandemic.
Immunotherapy & Mental Health: Learn how cancer care providers can better integrate mental health awareness into the immunotherapy care continuum and the mental health implications of treatment with cancer IO.
Survivorship Care After Immunotherapy: Learn about the transition from immunotherapy to post-treatment survivorship, how immunotherapy differs from chemotherapy after treatment, and why coordination and communication among providers, patients, and caregivers is essential.
Listen to the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts. You can also listen with your smart home device. For instructions on how to listen with Alexa, click here, or just tell Alexa to "Play CANCER BUZZ." For Google Home instructions, click here.
Additional tools and resources available in ACCC’s Precision Medicine Library provide the cancer care team with comprehensive, trusted, and tangible resources that can inform their patient care decisions and help improve outcomes. From toolkits to webinars, the library features resources developed and curated by cancer care experts throughout the world.
These resources offer information for clinicians from pharmacists to oncologists on all aspects of precision medicine, giving providers essential knowledge to apply to patient care and help bring clarity to complex care decisions.
Bringing CAR T-Cell Therapies to Community Oncology Gap Analysis
Bispecific Antibodies Checklist for Community Providers
Using Bispecific Antibodies in Community Practice
Biomarker Testing in Practice: Process Improvement Toolkit
Application of Biomarkers in Clinical Trials
The Business Case for Hiring a Certified Genetic Counselor
Immuno-Oncology Survivorship Templates
Immuno-Oncology Virtual Toxicity Article Series
Considerations for Pathology Reporting
Patient-Centered Care: Reporting and Communicating Pathology and Ancillary Test Results
Integration of Pathology with the Cancer Team Infographic
Operational Pathways for Biomarker Testing in NSCLC Environmental Scan
Explore the many terms associated with the different areas and applications of cancer biomarkers.
Biomarker Resource Library
Search this resource bank of nationally available materials relevant to cancer biomarkers and biomarker testing. You may filter by cancer type, area of application, and/or primary audience.
This practical toolkit is centered around the four key elements needed to develop a precision medicine program that successfully incorporates biomarker testing.
MRD Testing Implementation Roadmap
Navigate how to lay the groundwork for MRD testing, prepare your care team, implement testing, and evaluate ongoing progress.
MRD Testing Resource Library
Curated materials to help establish and implement MRD testing for your patients with adult B-cell ALL.
Biomarker Testing Implementation Roadmap for Advanced NSCLC
An innovative tool to implement, expand, and sustain biomarker testing for patients with advanced NSCLC.
Biomarker Testing Resource Library
Curated materials to support the implementation of biomarker testing for patients with advanced NSCLC.
Bispecific Antibodies Resources
Links to recent scholarship and resources that can help practices better serve their patients who may be eligible for TRBA therapy.
Presented at the 63rd ASH Annual Meeting, December 11-14, 2021, in Atlanta, GA.
Presented at the 2020 ASCO Virtual Scientific Program
Association of Community Cancer Centers Launches Precision Medicine Resource Library
Nov 17, 2021
As the precision medicine landscape evolves, ACCC supports the multidisciplinary cancer care team with education in the following areas:
A Multidisciplinary Consortium to Advance Genetic Counseling in Oncology
Biomarker Testing in Personalized Treatment Selection for Metastatic Colorectal Cancer
Biosimilars Education Center Overview
Bringing CAR T-Cell Therapies to Community Oncology
Changing Care Patterns for Patients with Early-Stage Non-Small Cell Lung Cancer
Comprehensive Quality Care for Patients with Small Cell Lung Cancer
Eliminating Precision Medicine Disparities
Emerging Biomarkers: Innovative Therapies for NTRK Gene Fusion Testing
Evolving Biomarkers in NSCLC
Integration of MRD Testing: A Pathway for Patients with B-Cell Acute Lymphoblastic Leukemia
Integration of Pathology with the Cancer Care Team
MRD Testing Implementation Roadmaps
Multi-Cancer Early Detection: Changes on the Horizon
Operational Pathways for Molecular Testing in NSCLC
Precision Medicine Stewardship
Preparing Community Providers for Bispecific Antibodies
Preparing for New Cellular Therapies: Tumor-Infiltrating Lymphocytes
Quality Improvement in Breast Cancer Through BRCA Testing